Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 3 (2006), Issue 5 (May)

1. Safety of simple cystectomy in patients with unilateral mucinous borderline tumors.
   Fertil Steril, 85(5): 1510.e1-4. [Abstract] [Full-text]
2. Loss of communication in ovarian cancer.
   Am J Obstet Gynecol, 194(5): e27-31. [Abstract] [Full-text]
3. Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic cancer cell lines and in rodent heart.
   Am J Obstet Gynecol, 194(5): e23-6. [Abstract] [Full-text]
4. Retrospective cohort study of surgical staging for ovarian low malignant potential tumors.
   Am J Obstet Gynecol, 194(5): e20-2. [Abstract] [Full-text]
5. Expression analysis and prognostic significance of the SRA1 gene, in ovarian cancer.
   Biochem Biophys Res Commun, 344(2): 667-74. [Abstract] [Full-text]
6. Characterization of RNASET2, the first human member of the Rh/T2/S family of glycoproteins.
   Arch Biochem Biophys, 449(1): 17-26. [Abstract] [Full-text]
7. Anthropometry and the risk of epithelial ovarian cancer.
   Cancer, 106(10): 2247-57. [Abstract] [Full-text]
8. Activating mutations of the stimulatory g protein in juvenile ovarian granulosa cell tumors: a new prognostic factor?
   J Clin Endocrinol Metab, 91(5): 1842-7. [Abstract] [Full-text]
9. Total-genome analysis of BRCA1/2-related invasive carcinomas of the breast identifies tumor stroma as potential landscaper for neoplastic initiation.
   Am J Hum Genet, 78(6): 961-72. [Abstract] [Full-text]
10. Performance characteristics of seven automated CA 125 assays.
    Am J Clin Pathol, 125(6): 921-7. [Abstract] [Full-text]
11. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer.
    Int J Cancer, 119(3): 599-607. [Abstract] [Full-text]
12. Molecular genetic evidence that endometriosis is a precursor of ovarian cancer.
    Int J Cancer, 119(3): 556-62. [Abstract] [Full-text]
13. Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors.
    Int J Cancer, 119(3): 712-7. [Abstract] [Full-text]
14. Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma.
    Mol Pharmacol, 69(6): 1801-9. [Abstract] [Full-text]
15. Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells.
    Cancer Chemother Pharmacol, 58(3): 384-95. [Abstract] [Full-text]
16. Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients.
    Cancer Chemother Pharmacol, 58(3): 319-25. [Abstract] [Full-text]
17. Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study.
    Gynecol Oncol, 101(3): 390-7. [Abstract] [Full-text]
18. Cystic clear cell tumor of borderline malignancy of the ovary lacking fibromatous components: report of two cases and a possible new histological subtype.
    Gynecol Oncol, 101(3): 540-4. [Abstract] [Full-text]
19. Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer.
    Gynecol Oncol, 101(3): 385-9. [Abstract] [Full-text]
20. Acquisition of chemoresistance following discontinuous exposures to cisplatin is associated in ovarian carcinoma cells with progressive alteration of FAK, ERK and p38 activation in response to treatment.
    Gynecol Oncol, 101(3): 507-19. [Abstract] [Full-text]
21. HSP-10 in ovarian cancer: expression and suppression of T-cell signaling.
    Gynecol Oncol, 101(3): 481-6. [Abstract] [Full-text]
22. Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer.
    Gynecol Oncol, 101(3): 495-8. [Abstract] [Full-text]
23. Gender of offspring and maternal ovarian cancer risk.
    Gynecol Oncol, 101(3): 476-80. [Abstract] [Full-text]
24. BRCA1 promoter methylation predicts adverse ovarian cancer prognosis.
    Gynecol Oncol, 101(3): 403-10. [Abstract] [Full-text]
25. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study.
    Gynecol Oncol, 101(3): 436-40. [Abstract] [Full-text]
26. Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up.
    Gynecol Oncol, 101(3): 423-8. [Abstract] [Full-text]
27. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
    Am J Obstet Gynecol, 194(6): 1702-9. [Abstract] [Full-text]
28. Ionizing radiation enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human ovarian cancer.
    J Cell Physiol, 208(2): 298-306. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.